Vimarsana
Biggest News Aggregation in the World

Feb 7 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Feb 7. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Feb 7 Today - Breaking & Trending Today

Jason Isbell to perform at Rhodes College campus | News - Vimarsana News

Jason Isbell to perform at Rhodes College campus | News

The event is free and open to the public, but there will be very limited seating available for those who do not register.

Kate McBrien to discuss true history of Malaga Island, Feb. 7 - Vimarsana News

Kate McBrien to discuss true history of Malaga Island, Feb. 7

LINCOLNVILLE — Kate McBrien will discuss the true history of the community who lived on Malaga Island, off the coast of Phippsburg, Maine, in the late 1800s. The discussion, Wednesday, February 7, at 6:30 p.m., at the Lincolnville Community Library...

Cass County Board: Financial activity revs up as tax season starts - Vimarsana News

Cass County Board: Financial activity revs up as tax season starts

Auditor-Treasurer's office receiving a lot of calls about truth-in-taxation notices and property tax statements.

Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment - Vimarsana News

Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment

MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug application (IND) for its innovative drug HP518, an oral chimeric degrader targeting androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). HP518 is currently in Phase I clinical trials in Australia. The open-label study approved ...

Related Topics:
Yuanwei ChenPrnewswire Hinova Pharmaceuticals IncDrug AdministrationPharmaceuticals IncFeb 7023 Prnewswire Hinova Pharmaceuticals Inc A Clinical Stage Biopharmaceutical Company Focusing On Developing Novel Therapeutics For Cancers And Metabolic DiseasesEcently Announced That The Us Food And Drug Administration Fda Has Cleared Company 39s Investigational New Application Ind For Its Innovative Hp518N Oral Chimeric Degrader Targeting Androgen Receptor Ar For The Treatment Of Metastatic Castration Resistant Prostate Cancer Mcrpc Hp518 Is Currently In Phasei Clinical Trials Australia Open Label Study Approved By Fda Will Assess SafetyNd Anti Tumor Activity Of Hp518 Quot Isa Novel Drug Expected To Address The Unmet Clinical Needs Prostate Cancer TreatmentUot Said Yuanwei ChenResident And Ceo Of Hinova Quot The Available Study Results Hp518 Strengthen Our Confidence That Isa Potentially New Treatment For Drug Resistant Prostate Cancer We Are Making Full Efforts To Advance ClinicalOping Hp518 Will Provide More Clinical Benefits To Patients Worldwide In The Future Quot Has Been Discovered And Developed Through Hinova 39s Targeted Protein Degradation Drug Discovery Platform It Potential Overcome Resistance Of Prostate Cancer That Is Due Some Specific Ar Mutations Isa Validated Therapeutic Target Treat During TreatmentRug Resistance Becomes Inevitable Due To Multiple MechanismsNcluding Ar Amplification Or MutationsTc In Preclinical StudiesP518 Showed Excellent Selectivity And Degradation Activity Against Wild Type Ar Some Specific Mutants That Are Resistant To Enzalutamide Hp518 Also Demonstrated Antitumor Efficacy In Xenograft Mouse Models About Hinova Is An International Clinical Stage Biopharmaceutical Company Engaged The Development Of Innovative Deuterated Chimeric Degraders For Cancers Metabolic Diseases Has Establisheda Targeted Protein Drug Discovery PlatformHich Allows Hinova To Screen For Protein Degradation Activity Rapidly And Accomplish Efficient Design Optimization Of Chimeric Degraders FurthermoreInova Has Profound Experience In Chemical Manufacturing Control Cmc Of Chimeric Degrader Compounds For More InformationLease Visit Http Www Hinovapharma Com En
Velocity 678 Comes Out of Stealth - Vimarsana News

Velocity 678 Comes Out of Stealth

SINGAPORE, Feb. 7, 2023 /PRNewswire/ --Velocity 678 (V678), a joint partnership between Momentum Commerce, SnT Global Logistics, and Aiken Group, is proud to announce its appointment of Kenneth Chiew as General Manager. Based in Singapore & Malaysia, V678 is a leading enabler in Southeast Asia, offering end-to-end live commerce solutions such as live streaming, short video content production, social media operation, strategy planning, TikTok shop management, campaign optimization, ecommerce operations, and influencer marketing. As Aiken Group's Social Commerce arm, V678 is also a notab...